Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice

Immunobiology

Volumn 211, Issue 1-2, 2006, Pages 11-27

  Lladser, Alvaro ^a   Párraga, Mario ^a,b   Quevedo, Licarallén ^a   Molina, Maria Carmen ^c   Silva, Soledad ^c   Ferreira, Arturo ^c   Billetta, Rosario ^c,d   Quest, Andrew F G ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSIDAD DE VALPARAÍSO   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

^d Androclus Therapeutics Inc   (United States)

Author keywords

Antigen engineering; Cancer; DNA immunization; Survivin; Tumor associated antigen

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G2A ANTIBODY; NAKED DNA; PLASMID DNA; SURVIVIN; TUMOR ANTIGEN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELLULAR IMMUNITY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; GENE TARGETING; GENETIC TRANSFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; MOUSE STRAIN; NONHUMAN; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH1 CELL; TUMOR IMMUNITY; UPREGULATION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

EID: 31444435676     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2005.08.002     Document Type: Article

References (95)

1. A.L. Ackerman C. Kyritsis R. Tampe P. Cresswell Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells Nat. Immunol. 6 2005 107-113
2. C. Adida P.L. Crotty J. McGrath D. Berrebi J. Diebold D.C. Altieri Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation Am. J. Pathol. 152 1998 43-49
3. G. Ambrosini C. Adida D.C. Altieri A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma Nat. Med. 3 1997 917-921
4. M.H. Andersen P.T. Straten Survivin-a universal tumor antigen Histol. Histopathol. 17 2002 669-675
5. M.H. Andersen L.O. Pedersen J.C. Becker P.T. Straten Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients Cancer Res 61 2001 869-872
6. M.H. Andersen L.O. Pedersen B. Capeller E.B. Brocker J.C. Becker P.T. Straten Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients Cancer Res. 61 2001 5964-5968
7. E. Apolloni V. Bronte A. Mazzoni P. Serafini A. Cabrelle D.M. Segal H.A. Young P. Zanovello Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes J. Immunol. 165 2000 6723-6730
8. R.M. Aris D.M. Maia I.P. Neuringer K. Gott S. Kiley K. Gertis J. Handy Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naive lung transplant recipient Am. J. Respir. Crit. Care Med. 154 1996 1712-1717
9. J.C. Becker P. Guldberg J. Zeuthen E.B. Brocker P.T. Straten Accumulation of identical T cells in melanoma and vitiligo-like leukoderma J. Invest. Dermatol. 113 1999 1033-1038
10. O.P. Blanc-Brude M. Mesri N.R. Wall J. Plescia T. Dohi D.C. Altieri Therapeutic targeting of the survivin pathway in cancer: Initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis Clin. Cancer Res. 9 2003 2683-2692
11. K. Brasel H.J. McKenna K. Charrier P.J. Morrissey D.E. Williams S.D. Lyman Flt3 ligand synergizes with granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice Blood 90 1997 3781-3788
12. V. Bronte D.B. Chappell E. Apolloni A. Cabrelle M. Wang P. Hwu N.P. Restifo Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation J. Immunol. 162 1999 5728-5737
13. V. Bronte E. Apolloni A. Cabrelle R. Ronca P. Serafini P. Zamboni N.P. Restifo P. Zanovello Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells Blood 96 2000 3838-3846
14. T. Cabrera M. Angustias Fernandez A. Sierra A. Garrido A. Herruzo A. Escobedo A. Fabra F. Garrido High frequency of altered HLA class I phenotypes in invasive breast carcinomas Hum. Immunol. 50 1996 127-134
15. V.W. Chan S. Kothakota M.C. Rohan L. Panganiban-Lustan J.P. Gardner M.S. Wachowicz J.A. Winter L.T. Williams Secondary lymphoid-tissue chemokine (SLC) is chemotactic for mature dendritic cells Blood 93 1999 3610-3616
16. J.T. Chang F.H. Wong C.T. Liao I.H. Chen H.M. Wang A.J. Cheng Enzyme immunoassay for serum autoantibody to survivin and its findings in head-and-neck cancer patients Clin. Chem. 50 2004 1261-1264
17. P.H. Chauvenet C.P. McArthur R.T. Smith Demonstration in vitro of cytotoxic T cells with apparent specificity toward tumor-specific transplantation antigens on chemically induced tumors J. Immunol. 123 1979 2575-2581
18. C.G. Clemente M.C. Mihm Jr. R. Bufalino S. Zurrida P. Collini N. Cascinelli Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma Cancer 77 1996 1303-1310
19. S. Coma V. Noe C. Lavarino J. Adan M. Rivas M. Lopez-Matas R. Pagan F. Mitjans S. Vilaro J. Piulats C.J. Ciudad Use of siRNAs and antisense oligonucleotides against survivin RNA to inhibit steps leading to tumor angiogenesis Oligonucleotides 14 2004 100-113
20. F.V. Cromme P.F. van Bommel J.M. Walboomers M.P. Gallee P.L. Stern P. Kenemans T.J. Helmerhorst M.J. Stukart C.J. Meijer Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours Brit. J. Cancer 69 1994 1176-1181
21. C.S. Dela Cruz J.W. Chamberlain K.S. MacDonald B.H. Barber Xenogeneic and allogeneic anti-MHC immune responses induced by plasmid DNA immunization Vaccine 17 1999 2479-2492
22. Q.L. Deveraux J.C. Reed IAP family proteins - suppressors of apoptosis Genes Dev. 13 1999 239-252
23. M.L. Disis K. Schiffman T.A. Gooley D.G. McNeel K. Rinn K.L. Knutson Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization Clin. Cancer Res. 6 2000 1347-1350
24. J.J. Donnelly M.A. Liu J.B. Ulmer Antigen presentation and DNA vaccines Am. J. Respir. Crit. Care Med. 162 2000 190-193
25. P.R. Dunbar C.L. Smith D. Chao M. Salio D. Shepherd F. Mirza M. Lipp A. Lanzavecchia F. Sallusto A. Evans R. Russell-Jones A.L. Harris V. Cerundolo A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response J. Immunol. 165 2000 6644-6652
26. D.M. Feltquate DNA vaccines: Vector design, delivery, and antigen presentation J. Cell Biochem. 30-31 Suppl. 1998 304-311
27. L. Fong D. Brockstedt C. Benike J.K. Breen G. Strang C.L. Ruegg E.G. Engleman Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy J. Immunol. 167 2001 7150-7156
28. A.G. Fraser C. James G.I. Evan M.O. Hengartner Caenorhabditis elegans inhibitor of apoptosis protein (IAP) homologue BIR-1 plays a conserved role in cytokinesis Curr. Biol. 9 1999 292-301
29. D.H. Fuller M.M. Corb S. Barnett K. Steimer J.R. Haynes Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques Vaccine 15 1997 924-926
30. E.F. Fynan H.L. Robinson R.G. Webster Use of DNA encoding influenza hemagglutinin as an avian influenza vaccine DNA Cell Biol. 12 1993 785-789
31. P. Gallo S. Dharmapuri M. Nuzzo D. Maldini M. Iezzi F. Cavallo P. Musiani G. Forni P. Monaci Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector Int. J. Cancer 113 2005 67-77
32. T. Gilewski S. Adluri G. Ragupathi S. Zhang T.J. Yao K. Panageas M. Moynahan A. Houghton L. Norton P.O. Livingston Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21 Clin. Cancer Res. 6 2000 1693-1701
33. G.V. Glinsky V.V. Glinsky A.B. Ivanova C.J. Hueser Apoptosis and metastasis: Increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms Cancer Lett. 115 1997 185-193
34. J.S. Gold C.R. Ferrone J.A. Guevara-Patino W.G. Hawkins R. Dyall M.E. Engelhorn J.D. Wolchok J.J. Lewis A.N. Houghton A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen J. Immunol. 170 2003 5188-5194
35. D. Grossman J.M. McNiff F. Li D.C. Altieri Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma J. Invest. Dermatol. 113 1999 1076-1081
36. D. Grossman P.J. Kim O.P. Blanc-Brude D.E. Brash S. Tognin P.C. Marchisio D.C. Altieri Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53 J. Clin. Invest. 108 2001 991-999
37. D. Grossman P.J. Kim J.S. Schechner D.C. Altieri Inhibition of melanoma tumor growth in vivo by survivin targeting Proc. Natl. Acad. Sci. USA 98 2001 635-640
38. S. Gurunathan D.M. Klinman R.A. Seder DNA vaccines: Immunology, application, and optimization Annu. Rev. Immunol. 18 2000 927-974
39. W.G. Hawkins J.S. Gold N.E. Blachere W.B. Bowne A. Hoos J.J. Lewis A.N. Houghton Xenogeneic DNA immunization in melanoma models for minimal residual disease J. Surg. Res. 102 2002 137-143
40. H. Kawasaki D.C. Altieri C.D. Lu M. Toyoda T. Tenjo N. Tanigawa Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer Cancer Res. 58 1998 5071-5074
41. T.W. Kim C.F. Hung M. Ling J. Juang L. He J.M. Hardwick S. Kumar T.C. Wu Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins J. Clin. Invest. 112 2003 109-117
42. A. Knuth B. Danowski H.F. Oettgen L.J. Old T-cell-mediated cytotoxicity against autologous malignant melanoma: Analysis with interleukin 2-dependent T-cell cultures Proc. Natl. Acad. Sci. USA 81 1984 3511-3515
43. H.K. Koh Cutaneous melanoma N. Engl. J. Med. 325 1991 171-182
44. K. Kusakabe K.Q. Xin H. Katoh K. Sumino E. Hagiwara S. Kawamoto K. Okuda Y. Miyagi I. Aoki K. Nishioka D. Klinman The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine J. Immunol. 164 2000 3102-3111
45. W.W. Leitner M.C. Seguin W.R. Ballou J.P. Seitz A.M. Schultz M.J. Sheehy J.A. Lyon Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites J. Immunol. 159 1997 6112-6119
46. F. Li D.C. Altieri The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression Cancer Res. 59 1999 3143-3151
47. F. Li G. Ambrosini E.Y. Chu J. Plescia S. Tognin P.C. Marchisio D.C. Altieri Control of apoptosis and mitotic spindle checkpoint by survivin Nature 396 1998 580-584
48. F. Li E.J. Ackermann C.F. Bennett A.L. Rothermel J. Plescia S. Tognin A. Villa P.C. Marchisio D.C. Altieri Pleiotropic cell-division defects and apoptosis induced by interference with survivin function Nat. Cell Biol. 1 1999 461-466
49. Z. Maciejewski Xenon photocoagulation in the treatment of some intraocular tumors Klin. Oczna. 43 1973 601-605
50. E. Maraskovsky K. Brasel M. Teepe E.R. Roux S.D. Lyman K. Shortman H.J. McKenna Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified J. Exp. Med. 184 1996 1953-1962
51. M. Mesri N.R. Wall J. Li R.W. Kim D.C. Altieri Cancer gene therapy using a survivin mutant adenovirus J. Clin. Invest. 108 2001 981-990
52. M. Mincheff S. Tchakarov S. Zoubak D. Loukinov C. Botev I. Altankova G. Georgiev S. Petrov H.T. Meryman Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial Eur. Urol. 38 2000 208-217
53. M. Monzo R. Rosell E. Felip J. Astudillo J.J. Sanchez J. Maestre C. Martin A. Font A. Barnadas A. Abad A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers J. Clin. Oncol. 17 1999 2100-2104
54. S.W. Muchmore J. Chen C. Jakob D. Zakula E.D. Matayoshi W. Wu H. Zhang F. Li S.C. Ng D.C. Altieri Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin Mol. Cell 6 2000 173-182
55. F.O. Nestle S. Alijagic M. Gilliet Y. Sun S. Grabbe R. Dummer G. Burg D. Schadendorf Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nat. Med. 4 1998 328-332
56. D.S. O'Connor J.S. Schechner C. Adida M. Mesri A.L. Rothermel F. Li A.K. Nath J.S. Pober D.C. Altieri Control of apoptosis during angiogenesis by survivin expression in endothelial cells Am. J. Pathol. 156 2000 393-398
57. R.A. Olie A.P. Simoes-Wust B. Baumann S.H. Leech D. Fabbro R.A. Stahel U. Zangemeister-Wittke A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy Cancer Res. 60 2000 2805-2809
58. M.L. Palomba W.K. Roberts T. Dao G. Manukian J.A. Guevara-Patino J.D. Wolchok D.A. Scheinberg A.N. Houghton CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma Clin. Cancer Res. 11 2005 370-379
59. C.H. Pan H.W. Chen M.H. Tao Modulation of immune responses to DNA vaccines by codelivery of cytokine genes J. Formos. Med. Assoc. 98 1999 722-729
60. E.K. Park B.Y. Soh Y.S. Jang J.H. Park G.H. Chung Immune induction and modulation in mice following immunization with DNA encoding F protein of respiratory syncytial virus Mol. Cell 12 2001 50-56
61. K.C. Parker M.A. Bednarek J.E. Coligan Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains J. Immunol. 152 1994 163-175
62. V. Pisarev B. Yu R. Salup S. Sherman D.C. Altieri D.I. Gabrilovich Full-length dominant-negative survivin for cancer immunotherapy Clin. Cancer Res. 9 2003 6523-6533
63. A.F. Quest E.S. Bardes W.Q. Xie E. Willott R.A. Borchardt R.M. Bell Expression of protein kinase C gamma regulatory domain elements containing cysteine-rich zinc-coordinating regions as glutathione S-transferase fusion proteins Methods Enzymol. 252 1995 153-167
64. H. Rammensee J. Bachmann N.P. Emmerich O.A. Bachor S. Stevanovic SYFPEITHI: Database for MHC ligands and peptide motifs Immunogenetics 50 1999 213-219
65. E. Raz D.A. Carson S.E. Parker T.B. Parr A.M. Abai G. Aichinger S.H. Gromkowski M. Singh D. Lew M.A. Yankauckas S.M. Baird G.H. Rhodes Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses Proc. Natl. Acad. Sci. USA 91 1994 9519-9523
66. J.C. Reed D.B. Wilson Cancer immunotherapy targeting survivin: commentary re: V Pisarev et al., full-length dominant-negative survivin for cancer immunotherapy. Clin. Cancer Res. 9 2003 6523-6533
67. S. Reker J.C. Becker I.M. Svane E. Ralfkiaer P.T. Straten M.H. Andersen HLA-B35-restricted immune responses against survivin in cancer patients Int. J. Cancer 108 2004 937-941
68. S. Reker A. Meier L. Holten-Andersen I.M. Svane J.C. Becker P.T. Straten M.H. Andersen Identification of novel survivin-derived CTL epitopes Cancer Biol. Ther. 3 2004 173-179
69. N. Renkvist C. Castelli P.F. Robbins G. Parmiani A listing of human tumor antigens recognized by T cells Cancer Immunol. Immunother. 50 2001 3-15
70. H.L. Robinson L.A. Hunt R.G. Webster Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA Vaccine 11 1993 957-960
71. J. Rohayem P. Diestelkoetter B. Weigle A. Oehmichen M. Schmitz J. Mehlhorn K. Conrad E.P. Rieber Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients Cancer Res. 60 2000 1815-1817
72. P. Romero P.R. Dunbar D. Valmori M. Pittet G.S. Ogg D. Rimoldi J.L. Chen D. Lienard J.C. Cerottini V. Cerundolo Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes J. Exp. Med. 188 1998 1641-1650
73. C.M. Rooney C.A. Smith C.Y. Ng S. Loftin C. Li R.A. Krance M.K. Brenner H.E. Heslop Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation Lancet 345 1995 9-13
74. S.A. Rosenberg J.C. Yang D.J. Schwartzentruber P. Hwu F.M. Marincola S.L. Topalian N.P. Restifo M.E. Dudley S.L. Schwarz P.J. Spiess J.R. Wunderlich M.R. Parkhurst Y. Kawakami C.A. Seipp J.H. Einhorn D.E. White Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat. Med. 4 1998 321-327
75. S. Sakaguchi Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses Annu. Rev. Immunol. 22 2004 531-562
76. M. Schmitz P. Diestelkoetter B. Weigle F. Schmachtenberg S. Stevanovic D. Ockert H.G. Rammensee E.P. Rieber Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides Cancer Res. 60 2000 4845-4849
77. M. Sedegah R. Hedstrom P. Hobart S.L. Hoffman Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein Proc. Natl. Acad. Sci. USA 91 1994 9866-9870
78. P. Serafini R. Carbley K.A. Noonan G. Tan V. Bronte I. Borrello High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells Cancer Res. 64 2004 6337-6343
79. S. Siegel A. Wagner N. Schmitz M. Zeis Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model Br. J. Haematol. 122 2003 911-914
80. J.I. Sin J.J. Kim K.E. Ugen R.B. Ciccarelli T.J. Higgins D.B. Weiner Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes Eur. J. Immunol. 28 1998 3530-3540
81. M. Sioud D. Sorensen Generation of an effective anti-tumor immunity after immunization with xenogeneic antigens Eur. J. Immunol. 33 2003 38-45
82. H.S. Swana D. Grossman J.N. Anthony R.M. Weiss D.C. Altieri Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer N. Engl. J. Med. 341 1999 452-453
83. K. Tanaka S. Iwamoto G. Gon T. Nohara M. Iwamoto N. Tanigawa Expression of survivin and its relationship to loss of apoptosis in breast carcinomas Clin. Cancer Res. 6 2000 127-134
84. J.B. Ulmer J.J. Donnelly S.E. Parker G.H. Rhodes P.L. Felgner V.J. Dwarki S.H. Gromkowski R.R. Deck C.M. DeWitt A. Friedman L.A. Hawe K.R. Leander D. Martinez H.C. Perry J.W. Shiver D.L. Montgomery M.A. Liu Heterologous protection against influenza by injection of DNA encoding a viral protein Science 259 1993 1745-1749
85. A.G. Uren T. Beilharz M.J. O'Connell S.J. Bugg R. van Driel D.L. Vaux T. Lithgow Role for yeast inhibitor of apoptosis (IAP)-like proteins in cell division Proc. Natl. Acad. Sci. USA 96 1999 10170-10175
86. F. Vanky E. Klein Specificity of auto-tumor cytotoxicity exerted by fresh, activated and propagated human T lymphocytes Int. J. Cancer 29 1982 547-553
87. V.E. Velculescu S.L. Madden L. Zhang A.E. Lash J. Yu C. Rago A. Lal C.J. Wang G.A. Beaudry K.M. Ciriello B.P. Cook M.R. Dufault A.T. Ferguson Y. Gao T.C. He H. Hermeking S.K. Hiraldo P.M. Hwang M.A. Lopez H.F. Luderer B. Mathews J.M. Petroziello K. Polyak L. Zawel W. Zhang X. Zhang F.G. Haluska J. Jen S. Sukumar G.M. Landes G.J. Riggins B. Vogelstein K.W. Kinzler Analysis of human transcriptomes Nat. Genet. 23 1999 387-388
88. B.M. Vose M. Moore Cultured human T-cell lines kill autologous solid tumours Immunol. Lett. 3 1981 237-241
89. B. Wang K.E. Ugen V. Srikantan M.G. Agadjanyan K. Dang Y. Refaeli A.I. Sato J. Boyer W.V. Williams D.B. Weiner Gene inoculation generates immune responses against human immunodeficiency virus type 1 Proc. Natl. Acad. Sci. USA 90 1993 4156-4160
90. R.A. Warnock J.J. Campbell M.E. Dorf A. Matsuzawa L.M. McEvoy E.C. Butcher The role of chemokines in the microenvironmental control of T versus B cell arrest in Peyer's patch high endothelial venules J. Exp. Med. 191 2000 77-88
91. R. Xiang N. Mizutani Y. Luo C. Chiodoni H. Zhou M. Mizutani Y. Ba J.C. Becker R.A. Reisfeld A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication Cancer Res. 65 2005 553-561
92. Z.Q. Xiang S. Spitalnik M. Tran W.H. Wunner J. Cheng H.C. Ertl Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus Virology 199 1994 132-140
93. A. Yagihashi K. Asanuma M. Nakamura J. Araya Y. Mano T. Torigoe D. Kobayashi N. Watanabe Detection of anti-survivin antibody in gastrointestinal cancer patients Clin. Chem. 47 2001 1729-1731
94. M. Zeis S. Siegel A. Wagner M. Schmitz M. Marget R. Kuhl-Burmeister I. Adamzik D. Kabelitz P. Dreger N. Schmitz A. Heiser Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells J. Immunol. 170 2003 5391-5397
95. J. Zhao T. Tenev L.M. Martins J. Downward N.R. Lemoine The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner J. Cell Sci. 113 Pt 23 2000 4363-4371